Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics

Reuters01-26 21:00

Mirum Pharmaceuticals Completes Acquisition of Bluejay <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus $(HDV)$ to its portfolio. Brelovitug, a fully human monoclonal antibody, holds Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency. The therapy is currently being evaluated in the global AZURE Phase 3 program, with topline results expected in the second half of 2026. Mirum acquired all outstanding shares of Bluejay through a combination of cash and common stock, with potential additional tiered sales-based milestone payments. The company is also evaluating strategic options for Bluejay’s additional investigational programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260126610526) on January 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606424896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606424896","market":"us","top_or_hot":-1,"title":"Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mirum Pharmaceuticals Completes Acquisition of Bluejay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> to its portfolio. Brelovitug, a fully human monoclonal antibody, holds Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency. The therapy is currently being evaluated in the global AZURE Phase 3 program, with topline results expected in the second half of 2026. Mirum acquired all outstanding shares of Bluejay through a combination of cash and common stock, with potential additional tiered sales-based milestone payments. The company is also evaluating strategic options for Bluejay’s additional investigational programs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260126610526) on January 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-26 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mirum Pharmaceuticals Completes Acquisition of Bluejay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> to its portfolio. Brelovitug, a fully human monoclonal antibody, holds Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency. The therapy is currently being evaluated in the global AZURE Phase 3 program, with topline results expected in the second half of 2026. Mirum acquired all outstanding shares of Bluejay through a combination of cash and common stock, with potential additional tiered sales-based milestone payments. The company is also evaluating strategic options for Bluejay’s additional investigational programs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260126610526) on January 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BJDX","symbol_name":"Bluejay Diagnostics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL3typFS:1","article_id":"2606424896","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606424896","pubTimestamp":1769432454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus  to its portfolio. Brelovitug, a fully human monoclonal antibody, holds Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency. The therapy is currently being evaluated in the global AZURE Phase 3 program, with topline results expected in the second half of 2026. Mirum acquired all outstanding shares of Bluejay through a combination of cash and common stock, with potential additional tiered sales-based milestone payments. The company is also evaluating strategic options for Bluejay’s additional investigational programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BJDX":"Bluejay Diagnostics Inc","BK4139":"生物科技","MIRM":"Mirum Pharmaceuticals, Inc.","BK4082":"医疗保健设备"},"translate_title":"Mirum Pharmaceuticals完成对Bluejay Therapeutics的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":0.9,"BJDX":0.9},"content_text":"Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics\n\n\n        Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus $(HDV)$ to its portfolio. Brelovitug, a fully human monoclonal antibody, holds Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency. The therapy is currently being evaluated in the global AZURE Phase 3 program, with topline results expected in the second half of 2026. Mirum acquired all outstanding shares of Bluejay through a combination of cash and common stock, with potential additional tiered sales-based milestone payments. The company is also evaluating strategic options for Bluejay’s additional investigational programs.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260126610526) on January 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606424896","isCrawlerRequest":true}